Given that PD-L1 expression in tumor cells has been associated with increased clinical benefit from PD-1 inhibition in some tumor types [4,63,64], these findings in GBC support the future possibility of PD-L1 targeted therapy in PD-L1 positive GBC patient subset. The gene discussed is CD274; the disease is neoplasm.